Abstract 227: Healthcare Cost Impact of Continued Anticoagulation With Rivaroxaban Versus Placebo in the EINSTEIN-Extension Trial Population

MLA

François Laliberté, et al. “Abstract 227: Healthcare Cost Impact of Continued Anticoagulation With Rivaroxaban Versus Placebo in the EINSTEIN-Extension Trial Population.” Circulation: Cardiovascular Quality and Outcomes, vol. 10, Mar. 2017. EBSCOhost, https://doi.org/10.1161/circoutcomes.10.suppl_3.227.

APA

François Laliberté, Concetta Crivera, Mike Durkin, Philip S. Wells, Bennett Levitan, Dominique Lejeune, Yongling Xiao, Jeff Schein, Lloyd Haskell, Patrick Lefebvre, Veronica Ashton, & Anthonie W. A. Lensing. (2017). Abstract 227: Healthcare Cost Impact of Continued Anticoagulation With Rivaroxaban Versus Placebo in the EINSTEIN-Extension Trial Population. Circulation: Cardiovascular Quality and Outcomes, 10. https://doi.org/10.1161/circoutcomes.10.suppl_3.227

Chicago

François Laliberté, Concetta Crivera, Mike Durkin, Philip S. Wells, Bennett Levitan, Dominique Lejeune, Yongling Xiao, et al. 2017. “Abstract 227: Healthcare Cost Impact of Continued Anticoagulation With Rivaroxaban Versus Placebo in the EINSTEIN-Extension Trial Population.” Circulation: Cardiovascular Quality and Outcomes 10 (March). doi:10.1161/circoutcomes.10.suppl_3.227.